OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Squadron Capital Llc Sells 10,131 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS) major shareholder Squadron Capital Llc sold 10,131 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $23.10, for a total transaction of $234,026.10. Following the completion of the sale, the insider directly owned 6,526,633 shares in the company, valued at $150,765,222.30. This represents a 0.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Squadron Capital Llc also recently made the following trade(s):

• On Friday, August 28th, Squadron Capital Llc sold 326,700 shares of OrthoPediatrics stock. The stock was sold at an average price of $23.04, for a total transaction of $7,527,168.00.
• On Wednesday, August 26th, Squadron Capital Llc sold 18,000 shares of OrthoPediatrics stock. The stock was sold at an average price of $24.28, for a total transaction of $437,040.00.
• On Tuesday, August 25th, Squadron Capital Llc sold 16,300 shares of OrthoPediatrics stock. The shares were sold at an average price of $24.74, for a total transaction of $403,262.00.
• On Monday, August 24th, Squadron Capital Llc sold 4,000 shares of OrthoPediatrics stock. The stock was sold at an average price of $25.75, for a total transaction of $103,000.00.

OrthoPediatrics Stock Down 1.3%

NASDAQ:KIDS opened at $23.00 on Wednesday. The company has a market capitalization of $600.53 million, a price-to-earnings ratio of -13.69 and a beta of 0.98. OrthoPediatrics Corp. has a one year low of $14.42 and a one year high of $26.74. The stock has a 50-day simple moving average of $21.61 and a 200 day simple moving average of $18.76. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The firm had revenue of $70.51 million during the quarter, compared to analyst estimates of $68.21 million. Sell-side analysts predict that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Key Stories Impacting OrthoPediatrics

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Analysts assigned OrthoPediatrics a consensus price target of $26.44, implying potential upside from recent trading levels and signaling continued confidence in the company’s long-term growth prospects. OrthoPediatrics Receives $26.44 Consensus Price Target
• Neutral Sentiment: The reported sales appear across related director, major-shareholder and beneficial-ownership filings, meaning some transactions may represent overlapping disclosures rather than entirely separate blocks of stock. After the transactions, the reporting holders still controlled approximately 6.53 million shares, indicating continued substantial exposure to KIDS. SEC Insider Transaction Filing
• Negative Sentiment: Director David R. Pelizzon and major shareholder Jennifer N. Pritzker reported sales of 326,700 shares on August 28 at an average price of $23.04, worth approximately $7.53 million. Each reduced their reported ownership by 4.76%, which may pressure the stock or raise concerns about insider confidence, although both retained large positions. SEC Major Shareholder Ownership Filing
• Negative Sentiment: The same holders, along with Squadron Capital LLC, reported additional sales of 10,131 shares on September 1 at $23.10, worth approximately $234,000 per reported transaction. The small 0.15% ownership reduction is less significant by itself, but reinforces the near-term insider-selling overhang. SEC Ownership Filing

Institutional Trading of OrthoPediatrics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. increased its position in OrthoPediatrics by 433.1% in the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after buying an additional 1,139 shares during the period. Legal & General Group Plc acquired a new position in shares of OrthoPediatrics during the second quarter valued at $34,000. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of OrthoPediatrics by 5,226.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after acquiring an additional 2,561 shares during the period. Caption Management LLC bought a new position in shares of OrthoPediatrics during the third quarter worth about $54,000. Finally, BNP Paribas Financial Markets grew its position in shares of OrthoPediatrics by 60.2% during the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,235 shares during the last quarter. 69.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on KIDS. TD Cowen restated a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Piper Sandler reiterated an “overweight” rating and set a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Needham & Company LLC increased their target price on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. BTIG Research raised their price target on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Finally, Truist Financial set a $22.00 price target on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.44.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.